Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481411 | 0.86 | AVPR1A (0.57) | FFAR2OXTRSLC6A7 | |
| SCHEMBL29396604 | 0.86 | AVPR1A (0.57) | FFAR2OXTRSLC6A7 | |
| SCHEMBL6017547 | 0.86 | AVPR1A (0.57) | FFAR2OXTRSLC6A7 | |
| SCHEMBL5741557 | 0.81 | SMN1; SMN2 (0.50) | HPGDMAPK1POLBSMN1; SMN2MEN1 | |
| SCHEMBL5741564 | 0.81 | SMN1; SMN2 (0.50) | HPGDMAPK1POLBSMN1; SMN2MEN1 | |
| SCHEMBL4417850 | 0.80 | OXTR (0.51) | HPGDMAPK1OXTRPOLBSMN1; SMN2 | |
| SCHEMBL8320159 | 0.80 | HPGD (0.44) | HPGDMAPK1OXTRPOLBSMN1; SMN2 | |
| SCHEMBL4419397 | 0.80 | HPGD (0.44) | HPGDMAPK1OXTRPOLBSMN1; SMN2 | |
| SCHEMBL301777 | 0.80 | OXTR (0.51) | HPGDMAPK1OXTRPOLBSMN1; SMN2 | |
| SCHEMBL4418365 | 0.79 | HPGD (0.43) | HPGDMAPK1OXTRPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725526-B1 | METHOD FOR PREPARING PYRROLIDINE OXIMES | SERONO LAB (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | PPOX, PGF, OXTR | HPGD 34/4885MAPK1 2512/4885FFAR2 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.